Pharmaceuticals

A rare disease drug's EU approval is revoked over 'misleading' data, impacting patients and signaling a new era of strict regulatory scrutiny for pharma giants.

Swiss drugmaker Idorsia's new financing buys precious time, fueling its blockbuster hopeful QUVIVIQ and securing its ambitious R&D pipeline.

New data on a once-weekly drug and a novel combination therapy signal a major shift in treating achondroplasia, moving the focus from height to quality of life.

As pharma giants battle with blockbuster drugs, one company is betting on a simple, non-systemic hydrogel. Is this the future of weight management?

A landmark FDA decision on Trodelvy reshapes metastatic TNBC care, offering new hope while directly confronting deep-seated racial disparities in treatment.

While national HIV rates fall, a new Johns Hopkins report reveals how a decade of policy neglect is fueling a devastating surge among Latino communities.

Valneva's latest AGM wasn't just procedural. A new expert Chair and key operational shifts reveal a company doubling down on its late-stage vaccine strategy.

Nomic Bio and the HESI OASIS Consortium partner to map liver toxicity using proteomics, fueling AI models to make drug development safer and more ethical.

Oramed leverages a strategic pivot into a diversified operator, seeing massive gains from its Alpha Tau stake and securing entry into the Russell 2000 index.

As MAPS announces its 2027 summit, the psychedelic field grapples with a critical question: can its visionary promise survive the harsh pressures of reality?

A new wave of disease-modifying therapies is poised to ignite the Huntington's disease market, projecting 14% annual growth and turning a field of despair into a high-stakes biotech race.

An award for an AI search tool seems routine, but Ask Ella signals a deeper rewiring of the life sciences industry, turning data drudgery into strategic speed.

A novel membrane technology promises to speed up production of next-gen medicines by solving a critical, energy-intensive bottleneck in pharmaceutical manufacturing.

ZOIA and Meta Healthcare's alliance brings a ready-to-use liquid nutrition to the US, promising to ease the daily burden for those with a rare metabolic disorder.

Vaxart’s COVID pill vaccine trial sees funding cut, yet new funds for data analysis signal a complex bet by BARDA on the future of pandemic response.

Positive Phase 3b data for Otsuka's centanafadine could revolutionize treatment for millions battling both ADHD and anxiety with a single, first-in-class drug.

Servier's new trial for a fatal pediatric epilepsy is more than a medical milestone; it's a strategic bet on high-risk, high-reward rare disease markets.

As the GLP-1 market booms, Vivani Medical's new semaglutide implant promises a 'set-and-forget' solution to the adherence crisis plaguing weight-loss drugs.

Professor Jason Chin’s Heinrich Wieland Prize signals a new era. His work in synthetic biology is enabling Constructive Bio to forge a new class of drugs.

By fast-tracking its novel oral drug for atopic dermatitis, Kymera isn't just advancing a treatment—it's validating a new class of medicine.